Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

OSUR - Orasure Technologies Inc.


IEX Last Trade
4.48
-0.050   -1.116%

Share volume: 2,221,193
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$4.53
-0.05
-1.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
0.90%
1 Month
0.67%
3 Months
-4.68%
6 Months
-42.04%
1 Year
-34.79%
2 Year
9.00%
Key data
Stock price
$4.48
P/E Ratio 
12.36
DAY RANGE
N/A - N/A
EPS 
$0.36
52 WEEK RANGE
$3.92 - $8.45
52 WEEK CHANGE
-$0.30
MARKET CAP 
334.066 M
YIELD 
N/A
SHARES OUTSTANDING 
74.568 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$766,487
AVERAGE 30 VOLUME 
$687,553
Company detail
CEO: Douglas Michels
Region: US
Website: http://www.orasure.com/
Employees: 470
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo

Recent news